Table 3.
Effect of MET and SM therapy on hepatic inflammation and oxidative stress parameters in HHTg rats.
| HHTg/C | HHTg/MET | HHTg/MET+SM | PMET | PMET+SM | |
|---|---|---|---|---|---|
| GSH/GSSG | 27.06 ± 2.41 | 39.44 ± 2.38 | 44.09 ± 2.64 ** | 0.01 | n.s. |
| SOD (U/mg protein) | 0.127 ± 0.01 | 0.152 ± 0.01 | 0.183 ± 0.01 | 0.05 | 0.01 |
| CAT (µM H2O2 min/mg protein) | 1437 ± 80 | 1311 ± 88 | 1662 ± 130 | n.s. | 0.05 |
| GPx (µM NADPH/min/mg protein) | 249 ± 14 | 272 ± 12 | 349 ± 15 | n.s. | 0.001 |
| 4-HNE (ng/mg protein) | 69.1 ± 4.4 | 47.7 ± 1.6 *** | 46.6 ± 1.4 | 0.001 | 0.05 |
| MDA (nM/mg protein) | 3.43 ± 0.37 | 2.10 ± 0.29 | 2.28 ± 0.14 *** | 0.01 | ns |
| MCP-1 (pg/mg protein) | 27.132 ± 1.494 | 27.187 ± 2.579 ** | 13.366 ± 1.074 ** | ns | 0.001 |
| TNFα (pg/mg protein) | 68.615 ± 5.493 | 54.114 ± 0.994 *** | 45.274 ± 0.984 | 0.01 | 0.05 |
| hsCRP (ng/mg protein) | 93.618 ± 7.824 | 68.836 ± 2.616 *** | 50.240 ± 2.423 * | 0.001 | 0.01 |
| Resistin (pg/mg protein) | 4.672 ± 0.315 | 3.715 ± 0.178 *** | 3.767 ± 0.161 | 0.01 | ns |
Values are expressed as means ± SEM; n = 6 for HHTg/C, n = 7 for HHTg/MET, n = 8 for HHTg/MET+SM; PMET—probability reflecting the effect of metformin monotherapy vs. the control group without any treatment, PMET+SM—probability reflecting the effect of metformin therapy vs. metformin + silymarin combination therapy; data analysed by two-way-ANOVA; Fisher’s post-hoc LSD test applied for multiple comparisons between groups; * p < 0.05, ** p < 0.01, *** p < 0.001, n.s.—the difference is not significant.